SCHEMBL14958426

SCHEMBL14958426

COC(=O)c1ccc(C=NO)n2cccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39
▸ NSD2 O96028 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ NR4A1 P22736 1/20 0.39
▸ APEX1 P27695 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ PTPN7 P35236 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ CTDSP1 Q9GZU7 1/20 0.39
▸ KMT2A Q03164 7/20 0.39
▸ MEN1 O00255 6/20 0.39
▸ USP2 O75604 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ NR4A2 P43354 3/20 0.38
▸ LMNA P02545 3/20 0.38
▸ ALDH1A1 P00352 4/20 0.36
▸ KDM4E B2RXH2 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14958424 1.00 MAPT (0.39) MAPTL3MBTL1TDP1NSD2POLB
SCHEMBL14958425 1.00 MAPT (0.39) MAPTL3MBTL1TDP1NSD2POLB
SCHEMBL14958413 0.84 ALDH1A1 (0.46) MAPTTDP1HSD17B10KMT2AMEN1
SCHEMBL21354382 0.78 NR4A2 (0.40) MAPTL3MBTL1TDP1POLBKMT2A
SCHEMBL21354384 0.78 NR4A2 (0.40) MAPTL3MBTL1TDP1POLBKMT2A
SCHEMBL20068336 0.76 MYC (0.49) MAPTTDP1HSD17B10KMT2AMEN1
SCHEMBL14957953 0.72 NR4A2 (0.41) MAPTTDP1RECQLHSD17B10KMT2A
SCHEMBL7824329 0.69 L3MBTL1 (0.72) MAPTL3MBTL1TDP1NSD2POLB
SCHEMBL7826399 0.69 L3MBTL1 (0.72) MAPTL3MBTL1TDP1NSD2POLB
SCHEMBL7824322 0.69 L3MBTL1 (0.72) MAPTL3MBTL1TDP1NSD2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2782449-B1 ISOXAZOLINE DERIVATIVES USED IN THE CONTROL OF ECTOPARASITES ANACOR PHARMACEUTICALS INC (US) 2016-08-03 — — EP disclosed
EP-2782449-A1 ISOXAZOLINE DERIVATIVES USED IN THE CONTROL OF ECTOPARASITES Anacor Pharmaceuticals, Inc. (US) 2014-10-01 — — EP disclosed
US-8546357-B2 Boron-containing small molecules for controlling ectoparasites ELI LILLY AND COMPANY (US) 2013-10-01 — — US disclosed
WO-2013078071-A1 ISOXAZOLINE DERIVATIVES USED IN THE CONTROL OF ECTOPARASITES ELI LILLY AND COMPANY (US) 2013-05-30 — — WO disclosed
US-20130131017-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2013-05-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131017-A1 BORON-CONTAINING SMALL MOLECULES BCL6B, BCL6, RB1 MAPT 461/4885L3MBTL1 2465/4885TDP1 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback